Loading...
01/11 03:11
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mix of positive and neutral factors. Strong financial performance, including revenue and EBITDA growth, and positive developments in product segments like Salix and Solta Medical, contribute to a positive outlook. However, concerns over the IRA impact on Xifaxan and limited details on the DURECT acquisition introduce some uncertainty. The shift away from share buybacks could be seen as a negative, but overall, the positive financial metrics and strategic focus on growth suggest a positive stock movement in the short term.
Revenue Revenue was $2.53 billion, up 5% on a reported basis and 4% on an organic basis compared to the same period a year ago. The increase was driven by strong performance in segments like Salix, Solta, and International regions such as EMEA and Canada.
Adjusted Gross Margin Adjusted gross margin was 70.6%, 30 basis points lower year-over-year. The slight decline was attributed to changes in segment mix and cost pressures.
Adjusted Operating Expenses Adjusted operating expenses were $1.16 billion, an increase of $61 million compared to the same period last year. The increase was due to investments in promotional efforts and operational activities.
Adjusted EBITDA Adjusted EBITDA was $871 million, an increase of $45 million or 5% year-over-year. This growth was driven by positive segment mix and tight cost management.
Adjusted Operating Cash Flow Adjusted operating cash flow was $442 million, up 34% versus the second quarter of 2024. The increase was due to double-digit adjusted EBITDA growth and favorable timing of cash interest payments.
Salix Revenue Salix revenues were $627 million, an increase of $69 million or 12% compared to the same period last year. Growth was driven by favorable net pricing across major brands like Xifaxan, Relistor, and Trulance, as well as strong volume performance.
International Revenue Revenues for the International segments were $278 million, an increase of 1% compared to the second quarter of last year. Growth in Canada and EMEA was offset by softness in LATAM due to macroeconomic challenges and channel destocking.
Solta Medical Revenue Revenues were $128 million, an increase of 25% on a reported basis and 26% on an organic basis compared to the same period last year. Growth was fueled by strong performance in South Korea and moderate growth in China, despite tariff-related headwinds.
Diversified Segment Revenue Revenues were $219 million, a decrease of 13% compared to the same period a year ago. The decline was due to nonrecurring elements like onetime pricing adjustments and unexpected demand in 2024, partially offset by strong Wellbutrin performance.
DURECT Corporation Acquisition: Bausch Health announced an agreement to acquire DURECT Corporation to develop its treatment for alcohol hepatitis, leveraging its hepatology expertise.
Next Generation Fraxel: Shipments began in June 2025 after its U.S. launch in April, indicating growth opportunities beyond the Asia Pacific region.
CABTREO and Ryaltris: CABTREO's launch in Canada has been successful, and Ryaltris has gained traction since its 2023 launch in the Canadian market.
RED-C Phase III Studies: Progressing on two global Phase III studies for RED-C, targeting liver disease, with data expected by early 2026.
Cardiometabolic Brands in Latin America: Launched in June 2025, targeting the fast-growing cardiometabolic market in Mexico.
Solta Medical Growth: Strong double-digit growth in South Korea and moderate growth in China despite tariff-related headwinds.
EMEA and Canada Growth: EMEA achieved 10 consecutive quarters of organic growth, and Canada saw solid results from promoted products.
Revenue and EBITDA Growth: Achieved 5% year-over-year revenue growth and 10% adjusted EBITDA growth, marking nine consecutive quarters of growth.
Debt Refinancing: Completed $7.9 billion refinancing to extend maturities and reduce high-interest debt.
AI-Based Sales Platform: Leveraged AI-based platform for Xifaxan and Relistor to drive new patient starts and sales.
Microbiome Skin Care Partnership: Partnered with YUN NV to launch probiotic-based skin care products in Poland, targeting acne and other skin conditions.
Capital Structure Optimization: Actively reducing high-interest debt and exploring options to extend 2028 maturities.
Tariff-related headwinds in China: Growth in China temporarily softened due to tariff-related headwinds in April and May, impacting Solta's performance.
LATAM macroeconomic challenges: Soft performance in LATAM due to ongoing macroeconomic challenges and partial channel destocking.
Debt burden and refinancing: The company has a significant debt burden of $16.1 billion and is actively working on refinancing and reducing high-interest debt, which poses financial risks.
Regulatory and acquisition risks: The acquisition of DURECT Corporation is subject to certain conditions, including shareholder approval, which could delay or complicate the process.
Concentration risk in International segment: While the EMEA business has a diversified portfolio, LATAM's performance is more vulnerable to macroeconomic conditions, increasing regional risk exposure.
Tariffs on U.S. imports to China: The timing of shipments to China was managed to minimize the impact of tariffs, indicating ongoing trade-related risks.
Neurology and dermatology revenue decline: The diversified segment saw a 13% revenue decline, driven by neurology and dermatology businesses, which had benefited from one-time pricing adjustments in 2024.
Economic uncertainties in LATAM: LATAM's softer performance is attributed to macroeconomic challenges, which could persist and impact future growth.
Revenue Guidance: Bausch Health reaffirms its full-year 2025 revenue guidance, expecting revenue between $4.95 billion and $5.1 billion, representing a 4% increase year-over-year at the midpoint.
Adjusted EBITDA Guidance: The company maintains its adjusted EBITDA outlook for 2025, projected to be between $2.625 billion and $2.725 billion, reflecting a 5% increase versus 2024 at the midpoint.
Adjusted Operating Cash Flow: Guidance for adjusted operating cash flow remains between $825 million and $875 million for 2025.
Pipeline Development: Bausch Health is progressing with two global Phase III studies for RED-C, targeting initial data readouts by early 2026. This product aims to address unmet needs in hepatology by slowing disease progression in cirrhotic patients.
Acquisition of DURECT Corporation: The company plans to close the acquisition of DURECT Corporation in Q3 2025, advancing the development of larsucosterol, a treatment for alcohol hepatitis, which currently lacks FDA or EMA-approved therapies.
Solta Medical Growth: Solta Medical segment shows strong growth potential, with double-digit growth in South Korea and expansion in the U.S. and Canada. The launch of the Next Generation Fraxel in the U.S. is expected to drive further growth.
International Segment Growth: The EMEA region achieved its 10th consecutive quarter of organic growth, with a diversified portfolio minimizing concentration risk. The Canadian market also shows strong growth, driven by promoted products like CABTREO and Ryaltris.
Cardiometabolic Market Expansion: Bausch Health launched cardiometabolic brands in Latin America, targeting one of the fastest-growing therapy areas in the Mexican pharmaceutical market.
Debt Refinancing and Capital Structure Optimization: The company completed a $7.9 billion debt refinancing in April 2025 and plans to use $900 million of liquidity to repay high-interest debt, improving its capital structure.
The selected topic was not discussed during the call.
The earnings call indicates strong growth in Bausch + Lomb and international segments, and strategic initiatives like debt refinancing and acquisitions bolster long-term prospects. Despite some revenue declines and conservative guidance adjustments, positive Q&A insights on Xifaxan's growth and RED-C trials suggest optimism. Market reaction should be positive, with a projected 2-8% stock price increase, considering the company's market cap and strategic positioning.
The earnings call presents a mix of positive and neutral factors. Strong financial performance, including revenue and EBITDA growth, and positive developments in product segments like Salix and Solta Medical, contribute to a positive outlook. However, concerns over the IRA impact on Xifaxan and limited details on the DURECT acquisition introduce some uncertainty. The shift away from share buybacks could be seen as a negative, but overall, the positive financial metrics and strategic focus on growth suggest a positive stock movement in the short term.
The earnings call presents mixed signals: financial results show modest revenue growth and debt reduction, but margins have declined and refinancing increased costs. The guidance is optimistic, yet management's vague responses in Q&A raise concerns. The market cap suggests a moderate reaction. Overall, the sentiment is neutral, with no strong catalysts to drive significant stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
